Dr. Falk serves as director of the Vitreoretinal Fellowship Program at Albany Medical College.

She completed a vitreoretinal fellowship at the University of Texas - Houston and Albany Medical Center. She completed her residency at Hahnemann University Hospital in Philadelphia and earned her medical degree from SUNY Upstate Medical University in Syracuse.

Involvement in multiple investigational studies has enabled Dr. Falk and the Retina Consultants to introduce novel treatments for previously blinding eye conditions to the Capital Region. The first anti-VEGF therapies for wet macular degeneration with both Lucentis (RhuFab) and Macugen (Pegaptanib) were administered at Retina Consultants. Other treatments brought to the region were the first biodegradable Posurdex dexamethasone implant for central retinal vein occlusions, a Phase III injectable Triamcinolone Acetonide for diabetic macular edema, and systematic treatment with investigational monoclonal antibodies for noninfectious uveitis.

Dr. Falk is the principle investigator on numerous multi-center clinical trials. Her research covers the entire spectrum of medical, surgical, and inflammatory conditions of the eye. Her clinical research interests include new and experimental protocols and devices for the monitoring and treatment of macular degeneration, venous occlusions, arterial occlusions, diabetic retinopathy, and inflammatory diseases of the eye.